<DOC>
	<DOCNO>NCT01588509</DOCNO>
	<brief_summary>This phase 1 , randomize , open-label , parallel group study conduct healthy postmenopausal woman low bone mineral density previously treat alendronate .</brief_summary>
	<brief_title>Transition From Alendronate AMG 785</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Postmenopausal woman , define vaginal bleeding spot ≥ 12 month Low bone mineral density screen [ define bone mineral density ( BMD ) Tscore ≤ 2.0 ≥ 4.0 lumbar spine ( L1 L4 ; BMD Tscore evaluable vertebra ) , total hip , femoral neck ] Currently take alendronate ( 70 mg weekly equivalent ) exclusively ≥ 1 year verbal agreement subject take ≥ 80 % dos good tolerance History vertebral fracture , fragility fracture wrist , humerus , hip pelvis age 50 ; recent bone fracture within 6 month prior screen History metabolic bone disease Paget 's disease , rheumatoid arthritis , osteomalacia , osteogenesis imperfecta , osteopetrosis , ankylose spondylitis , Cushing 's disease , hyperprolactinemia , malabsorption syndrome Vitamin D deficiency ( define 25OHVitD level &lt; 20 ng/mL )</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>AMG 785 , bone mineral density , alendronate</keyword>
</DOC>